The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kesimpta, a CD20-directed cytolytic monoclonal antibody, is the first B-cell therapy intended for patient self-administration. The Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab ...

Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis presented study data at the sixth annual ...

Patients with relapsing forms of multiple sclerosis have a new treatment that can be self-administered at home. The Food and Drug Administration has approved Novartis’ Kesimpta (ofatumumab, formerly ...

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta ® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of ...

The US Food and Drug Administration (FDA) has approved Novartis’ relapsing multiple sclerosis (MS) treatment Kesimpta, one of the company’s most promising growth drivers as identified by CEO Vas ...

Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable ...

Kesimpta is a prescription drug used to treat specific types of multiple sclerosis (MS) as well as clinically isolated syndrome (CIS). Common side effects of Kesimpta include back pain, upper ...

Kesimpta can cause injection site reactions, headache, back pain, and other side effects. Kesimpta reduces immune system activity, which increases your risk of getting sick more easily than usual.